Recombinant protein corresponding to human Interleukin 1 beta expressed in E. coli. Cellular Localization: Secreted.
Interleukin 1 (IL-1) activates T cells and lymphocytes, which then proliferate and secrete interleukin 2. IL-1 is primarily released from stimulated macrophages and monocytes, but also is released from several other cell types, and is thought to play a key role in inflammatory and immune responses. The two closely related agents, interleukin1 alpha (IL-1 alpha) and interleukin1 beta (IL-1 beta) bind to the same cell surface receptor, elicit nearly identical biological responses and share 25% homology in their amino acid sequence. Applications: Suitable for use in ELISA, Western Blot, Flow Cytometry, Immunocytochemistry, and Neutralization. Other applications not tested. Recommended Dilutions: Western Blot: 1ug/ml using THP-1 human acute monocytic leukemia cell line treated with PMA and LPS Flow Cytometry: 2.5ug/10(6) cells. Using human peripheral bllod mononuclear cells treated with LPS, fixed with paraformaldehyde and permeabilized with saponin. Immunocytochemistry: 8-25ug/ml using immerson fixed human peripheral bllod mononuclear cells stimulated with LPS or with LPS and monensin. Neutralization: Measured by its ability to neutralize IL1beta/IL1F2induced proliferation in the D10.G4.1 mouse helper T cell line. The Neutralization Dose (ND50) is typically 0.0010.003ug/ml in the presence of 50pg/ml recombinant Human IL-1beta/IL-1F2 and 1.25ug/ml concanavalin A. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
